CN104582722A - 作为疫苗的艰难梭菌多肽 - Google Patents

作为疫苗的艰难梭菌多肽 Download PDF

Info

Publication number
CN104582722A
CN104582722A CN201380045505.3A CN201380045505A CN104582722A CN 104582722 A CN104582722 A CN 104582722A CN 201380045505 A CN201380045505 A CN 201380045505A CN 104582722 A CN104582722 A CN 104582722A
Authority
CN
China
Prior art keywords
seq
antigen
polypeptide
difficile
toxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380045505.3A
Other languages
English (en)
Chinese (zh)
Inventor
C·加莱奥蒂
R·里犹兹
M·皮萨
M·斯卡塞利
M·乌尼克里西南
M·马丁内利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201216748A external-priority patent/GB201216748D0/en
Priority claimed from GB201216749A external-priority patent/GB201216749D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104582722A publication Critical patent/CN104582722A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380045505.3A 2012-09-19 2013-09-19 作为疫苗的艰难梭菌多肽 Pending CN104582722A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201216748A GB201216748D0 (en) 2012-09-19 2012-09-19 Methods of treatment
GB1216749.0 2012-09-19
GB201216749A GB201216749D0 (en) 2012-09-19 2012-09-19 Antigen combinations
GB1216748.2 2012-09-19
PCT/IB2013/058673 WO2014045226A1 (en) 2012-09-19 2013-09-19 Clostridium difficile polypeptides as vaccine

Publications (1)

Publication Number Publication Date
CN104582722A true CN104582722A (zh) 2015-04-29

Family

ID=49725168

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380045505.3A Pending CN104582722A (zh) 2012-09-19 2013-09-19 作为疫苗的艰难梭菌多肽

Country Status (13)

Country Link
US (1) US9932374B2 (enExample)
EP (1) EP2897637A1 (enExample)
JP (1) JP2015529677A (enExample)
KR (1) KR20150056540A (enExample)
CN (1) CN104582722A (enExample)
AU (1) AU2013319821A1 (enExample)
BR (1) BR112015004629A2 (enExample)
CA (1) CA2882620A1 (enExample)
IL (1) IL237172A0 (enExample)
MX (1) MX2015002485A (enExample)
RU (1) RU2015106916A (enExample)
SG (1) SG11201500980WA (enExample)
WO (1) WO2014045226A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012245904B2 (en) 2011-04-22 2016-04-21 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
GB2525177A (en) * 2014-04-14 2015-10-21 New Royal Holloway & Bedford Vaccine
WO2016131157A1 (en) * 2015-02-19 2016-08-25 Immune Biosolutions Inc Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN112703006A (zh) 2018-06-19 2021-04-23 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1000155A1 (en) * 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
CA2404260A1 (en) * 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
WO2001094599A1 (en) 2000-06-07 2001-12-13 Smittskyddsinstitutet Gene expression cassette and its use
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
WO2004041857A2 (en) 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
WO2008152429A1 (en) 2007-06-14 2008-12-18 Health Protection Agency Chemically modified peptides with improved immunogenicity
JP2011512817A (ja) * 2008-02-28 2011-04-28 スリーエム イノベイティブ プロパティズ カンパニー クロストリジウム・ディフィシル胞子に対する抗体及びその使用
WO2011060431A2 (en) 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
AU2010325992A1 (en) 2009-12-02 2012-05-31 Tufts University Atoxic recombinant holotoxins of Clostridium difficile as immunogens
CN103974718A (zh) 2011-12-08 2014-08-06 诺华股份有限公司 基于艰难梭菌毒素的疫苗

Also Published As

Publication number Publication date
US9932374B2 (en) 2018-04-03
KR20150056540A (ko) 2015-05-26
IL237172A0 (en) 2015-04-30
CA2882620A1 (en) 2014-03-27
AU2013319821A1 (en) 2015-02-26
WO2014045226A1 (en) 2014-03-27
RU2015106916A (ru) 2016-11-10
BR112015004629A2 (pt) 2017-11-21
JP2015529677A (ja) 2015-10-08
EP2897637A1 (en) 2015-07-29
MX2015002485A (es) 2015-06-05
US20150315248A1 (en) 2015-11-05
SG11201500980WA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
CN109248313B (zh) 用于免疫接种以抵御金黄色葡萄球菌的组合物
US9694063B2 (en) Clostridium difficile toxin-based vaccine
US9932374B2 (en) Clostridium difficile polypeptides as vaccine
US10279026B2 (en) Antigens and antigen combinations
US9802988B2 (en) Engineered type IV pilin of Clostridium difficile
US9310381B2 (en) Engineered type IV pilin of Clostridium difficile
US20190290748A1 (en) Antigens and antigen combinations
US10105429B2 (en) Escherichia coli vaccine combination
WO2020078420A1 (en) Immunogenic preparations and methods against clostridium difficile infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150429